BioXcel Therapeutics, Inc. (BTAI) Gross margin 2022–2025
BioXcel Therapeutics, Inc. (BTAI) gross margin by fiscal year — reported gross profit divided by reported revenue.
74.5%FY2025 · since FY2022: 94.7% → 74.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 74.5% | +69.0 pp |
| FY2024 | 5.4% | -3.3 pp |
| FY2023 | 8.7% | -86.0 pp |
| FY2022 | 94.7% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice